Research study · Cancers · 2026
Does Cannabinoid Use Reduce Opioid Utilization Among Patients with Gastrointestinal Cancer? Evidence from Epic COSMOS
Verified on PubMed Clinical Evidence Analysis
A 2026 study in Cancers tested cannabinoids in cancer. It made no difference. Patients who received medical cannabis prescriptions were actually more likely to use opioid medications and used them for more days than those who did not receive cannabis. This study examines real world medical record data to show that prescription cannabis use during.
In plain language
Study overview
Researchers studied whether patients with digestive system cancers who received prescriptions for Food and Drug Administration-approved cannabis medications during early chemotherapy reduced their reliance on opioid pain medications. They analyzed electronic health records from a large national network of health systems covering more than one hundred forty thousand patients over a multi-year period.
Findings
It made no difference. Patients who received medical cannabis prescriptions were actually more likely to use opioid medications and used them for more days than those who did not receive cannabis. Cannabis prescriptions were most common among patients with pancreatic cancer and among Black patients.
Explore Dr. Caplan's interactive tool detailing cytochrome P450 pathways, clinical titration intervals, and physician surveillance rules.
The deeper readScientific analysis
Purpose: Whether medical cannabis reduces opioid use during early chemotherapy remains unclear. We examined cannabinoid and opioid prescribing among patients with GI cancers initiating chemotherapy. Methods: Patients with GI cancers initiating chemotherapy (2016–2025) were identified from the Epic COSMOS database. Cannabis exposure was defined as prescriptions for FDA-approved cannabinoids recorded in the EHR; non-prescription cannabis obtained through dispensaries were not captured. Patients with any cannabis or opioid use in the prior year or death within 90 days were excluded. Multivariable logistic regression evaluated factors associated with cannabinoid use. Results: Among 144,981 patients, 2.4% received cannabinoids within 90 days of chemotherapy initiation. Cannabinoid recipients were more likely to receive opioids than nonrecipients (60.6% vs. 31.1%, p < 0.01). In adjusted analyses, cannabinoid prescribing was more common among Black patients (aOR 1.45; 95%CI 1.30–1.61), women (aOR 1.11; 95%CI 1.03–1.19), and individuals with pancreatic cancer (aOR 3.26; 95%CI 2.97–3.58). Prescribing varied by region and declined over time, relative to 2017. Conclusions: Early cannabinoid prescribing was not associated with reduced opioid use. Use was more common among patients with pancreatic cancer and among Black patients, highlighting clinical and structural variation in supportive-care practices.
The paper
Citation
Worku EB, Woldesenbet SA, Pawlik TM Does Cannabinoid Use Reduce Opioid Utilization Among Patients with Gastrointestinal Cancer? Evidence from Epic COSMOS. Cancers (2026). PubMed 41976333 · DOI
Limitations the authors noted
The dataset captures only Food and Drug Administration-approved cannabinoid prescriptions documented in electronic health records, missing non-prescription cannabis obtained through state dispensaries or recreational markets. Lack of standardized symptom-severity scores prevented direct adjustment for confounding by indication, meaning cannabinoid prescriptions likely served as a proxy for higher symptom burden or more advanced disease. Retrospective observational design precludes causal inferences regarding the impact of cannabinoids on opioid utilization. Contextual determinants such as state cannabis policies, individual insurance coverage, and product availability could not be directly linked to patient-level records.
In practice
Why this matters
This study examines real world medical record data to show that prescription cannabis use during early cancer chemotherapy does not currently replace opioid use. It highlights that cannabis medicines are typically given to patients who are already sicker or experiencing more severe symptoms, rather than serving as a direct substitute for strong pain medications. Clinicians must recognize that legal access and cannabis prescribing patterns vary widely based on demographics and disease type, pointing to the need for careful symptom management and equity in supportive cancer care.
Frequently asked questions
Clinical Questions & Answers
What were the primary clinical findings regarding Cannabinoids and Cancer?
It made no difference. Patients who received medical cannabis prescriptions were actually more likely to use opioid medications and used them for more days than those who did not receive cannabis. Cannabis prescriptions were most common among patients with pancreatic cancer and among Black patients.
What study limitations or clinical safeguards should patients keep in mind?
The dataset captures only Food and Drug Administration-approved cannabinoid prescriptions documented in electronic health records, missing non-prescription cannabis obtained through state dispensaries or recreational markets. Lack of standardized symptom-severity scores prevented direct ad...
Browse related research
Condition: Cancer Condition: Opioid use Condition: Pain Topic: Cannabinoids Topic: Cannabis Topic: Medical cannabis
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on October 29, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.